Table 3.

Summary of patient outcome with respect to IKZF1 mutation status in multivariable analyses.

Complete remission	OR [95%-CI]	p
Mutated IKZF1	0.45 [0.22–0.91]	0.026
Age	0.95 [0.94–0.95]	<0.001
ELN2022 favorable risk	2.92 [1.81–4.71]	<0.001
ELN2022 intermediate risk	1.49 [0.94–2.37]	0.091
ELN2022 adverse risk	0.55 [0.36–0.85]	0.007
de novo AML	1.93 [1.13–3.30]	0.017
sAML	1.74 [0.95–3.19]	0.073
Event-free survival	HR [95%-CI]	p
mutated IKZF1	1.59 [1.15–2.18]	0.004
age	1.02 [1.02–1.03]	<0.001
ELN2022 favorable risk	0.53 [0.42–0.66]	<0.001
ELN2022 intermediate risk	0.95 [0.76–1.19]	0.678
ELN2022 adverse risk	1.56 [1.27–1.94]	<0.001
de novo AML	0.90 [0.69–1.18]	0.446
sAML	0.83 [0.61–1.12]	0.227
Relapse-free survival	HR [95%-CI]	p
mutated IKZF1	1.87 [1.17–3.00]	0.009
age	1.02 [1.02–1.03]	<0.001
ELN2022 favorable risk	0.58 [0.43–0.78]	<0.001
ELN2022 intermediate risk	1.00 [0.74–1.35]	0.935
ELN2022 adverse risk	1.30 [0.96–1.75]	0.087
de novo AML	1.07 [0.70–1.63]	0.767
sAML	0.98 [0.61–1.57]	0.925
Overall survival	HR [95%-CI]	p
Mutated IKZF1	1.68 [1.22–2.32]	0.002
Age	1.03 [1.03–1.04]	<0.001
ELN2022 favorable risk	0.56 [0.44–0.72]	<0.001
ELN2022 intermediate risk	1.00 [0.78–1.27]	0.981
ELN2022 adverse risk	1.50 [1.19–1.88]	0.001
de novo AML	0.80 [0.61–1.06]	0.123
sAML	0.79 [0.58–1.08]	0.143

Square brackets show 95%-confidence intervals. Boldface indicates statistical significance (p < 0.05).

HR hazard ratio, OR odds ratio, sAML secondary AML (sAML).